sodium iodide I 131, Iodotope, Sodium Iodide I 131 Therapeutic

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

Cancer 101: Cancer Explained

SIDE EFFECTS: The side effects commonly seen with sodium iodide I 131 treatment are mild with the smaller doses given for hyperthyroidism but may be more severe with the larger doses given for thyroid cancer. Sodium iodide I 131 may cause suppression of the bone marrow, resulting in anemia, and reductions in white blood cells and platelets. It also may cause acute leukemia.

Other important side effects that can occur with large doses include symptoms of:

Thyroid crisis (due to the release of large amounts of thyroid hormone), severe inflammation of the salivary glands, and chromosomal abnormalities may occur. On day three after treatment, a constellation of signs and symptoms may occur including:

Finally, temporary hair thinning may occur two to three months after treatment.

GENERIC AVAILABLE: Yes

PRESCRIPTION: Yes

PREPARATIONS: Capsules; with radioactivity of 0.75 to 100 mCi per capsule. (A millicurie is a unit for measuring activity). Sodium iodide I 131also is available as a liquid in vials containing 5 to 150 mCi/vial.

STORAGE: Sodium iodide I 131 should be store at room temperature, 20-25 C (68-77 C). Sodium iodide I 131 is ordered for individual patients in a hospital setting. It arrives at room temperature in a lead container to minimize radiation exposure to hospital personnel. Special handling is required.

DOSING: The usual sodium iodide I 131 dose ranges from 4-10 mCi to treat hyperthyroidism. Doses to treat thyroid cancer are individualized and are usually 10-27 times greater than for hyperthyroidism.

DRUG INTERACTIONS: Non-radioactive iodine, thyroid hormone, propylthiouracil (PTU) or methimazole (Tapazole, Northyx) may all interfere with the trapping of sodium iodide I 131 by the thyroid gland. Thyroid hormone, drugs that contain iodine (for example, amiodarone [Coradone]), and iodine containing contrast agents all interfere with the action of sodium iodide I 131.

PREGNANCY: Sodium iodide I 131 has been shown to cause harm to a developing fetus. Use in pregnant women should be avoided.

NURSING MOTHERS: Iodine is excreted in breast milk. Therefore, formula feedings for infants are strongly recommended for nursing women requiring sodium iodide I 131 treatment.

Medically reviewed by Eni Williams, PharmD

Reference: FDA Prescribing Information

Medically Reviewed by a Doctor on 7/24/2015

Quick GuidePancreatic Cancer Symptoms, Causes, and Treatment

Pancreatic Cancer Symptoms, Causes, and Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors